Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Director · Chief Executive Officer | May 25, 2022 | May 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date May 25, 2022 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 381,851 |
Ending reported balance
After 2022-05-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-25 · Purchase · Acquired 70,000 · Balance 354,851 Row 2 · 2022-05-26 · Purchase · Acquired 27,000 · Balance 381,851 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2032-02-17 | Direct | 2,516,939 |
Reported balance
After 2022-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-17 · Grant · Acquired 200,000 · Balance 2,516,939 F1: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2022 Filed May 27, 2022 14:05 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 27,000 | $0.53 | $14,215.50 |
DisclosureSEC source: 0001493152-22-015294 · ownership.xml · nonDerivative · entry 2 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,851 Read SEC document |
| May 25, 2022 Filed May 27, 2022 14:05 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | PurchaseCommon Stock | 70,000 | $0.49 | $34,083.00 |
DisclosureSEC source: 0001493152-22-015294 · ownership.xml · nonDerivative · entry 1 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,851 Read SEC document |
| February 17, 2022 Filed Feb 24, 2022 19:00 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 200,000 | Not disclosed Strike: $1.40 | Not disclosed |
DisclosureSEC source: 0001493152-22-005440 · ownership.xml · derivative · entry 1 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-17 F1 · security: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · price: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · derivative.exercise_date: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. Read SEC document |
| February 17, 2022 Filed May 27, 2022 14:05 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 200,000 | Not disclosed Strike: $1.40 | Not disclosed |
DisclosureSEC source: 0001493152-22-015294 · ownership.xml · derivative · entry 3 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,516,939 Underlying: Common Stock · 200,000 shares Expires 2032-02-17 F1 · security: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9. F1 · price: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9. F1 · derivative.exercise_date: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 6,585 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 8 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,585 Underlying: Common Stock · 6,585 shares Expires 2029-03-14 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 658,500 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 7 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,500 Underlying: Common Stock · 658,500 shares Expires 2029-02-28 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 817,560 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 6 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,560 Underlying: Common Stock · 817,560 shares Expires 2028-02-05 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 460,950 | Not disclosed Strike: $1.83 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 5 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,950 Underlying: Common Stock · 460,950 shares Expires 2027-01-04 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 263,400 | Not disclosed Strike: $3.19 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 4 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,400 Underlying: Common Stock · 263,400 shares Expires 2026-01-15 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 9,994 | Not disclosed Strike: $3.21 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 3 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,994 Underlying: Common Stock · 9,994 shares Expires 2022-12-21 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 99,950 | Not disclosed Strike: $3.21 | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 2 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,950 Underlying: Common Stock · 99,950 shares Expires 2022-12-01 F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 18:11 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantCommon Stock | 284,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000618 · edgar.xml · nonDerivative · entry 1 Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,851 F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.